Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Allogeneic stem cell transplantation (Allo-SCT) in multiple myeloma (MM) remains a
controversial topic because of a high risk of relapse and a significant transplant-related
mortality (TRM). In an effort to reduce the TRM, most allogeneic transplants in MM are now
performed after reduced-intensity conditioning regimens. In these conditions, TRM usually
range from 10 to 20%. However, reducing the intensity of the conditioning invariably
increases the incidence of relapse to 45 to 60%. As a consequence, post-transplant strategies
to reduce the incidence of relapse after reduced-intensity Allo-SCT should be considered and
evaluated.